Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
In view of the global emergency posed by lack of access to highly active antiretroviral therapy (HAART) and the limitations of current drug regimens, alternative therapeutic strategies are urgently needed. Cellular immune responses elicited by HIV-1 exert some control over virus replication, therefore the enhancement of HIV-1-specific responses by therapeutic vaccination might lead to viral containment without HAART. We evaluated the safety and immunogenicity, in HIV-1-infected individuals under HAART suppression, of a DNA vaccine, pTHr.HIVA.
Dorrell
Lucy
L
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK.
Yang
Hongbing
H
Iversen
Astrid Kn
AK
Conlon
Christopher
C
Suttill
Annie
A
Lancaster
Mary
M
Dong
Tao
T
Cebere
Inese
I
Edwards
Anne
A
Rowland-Jones
Sarah
S
Hanke
Tomás
T
McMichael
Andrew J
AJ
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D004341:Drug Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D015750:Genes, gag / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
D016915:AIDS Vaccines; D000939:Epitopes; D019444:Vaccines, DNA; C509463:pTHr.HIVA